<?xml version="1.0" encoding="UTF-8"?>
<p>Administration of F(ab′)
 <sub>2</sub> resulted in 100% protection (
 <xref ref-type="fig" rid="F2">Fig. 2A</xref>), and the F(ab′)
 <sub>2</sub>-treated NHPs did not lose substantial amounts of body weight during the experiment (
 <xref ref-type="fig" rid="F2">Fig. 2B</xref>). Fever was observed at 4 to 7 dpi in all animals, but temperatures returned to baseline by 8 dpi (
 <xref ref-type="fig" rid="F2">Fig. 2C</xref>), and F(ab′)
 <sub>2</sub>-treated NHPs showed virtually no observable signs of disease throughout the course of the experiment (
 <xref ref-type="fig" rid="F2">Fig. 2D</xref>). In contrast, control animals died at 7 or 8 dpi with clinical scores of over 30 and symptoms consistent with EVD. Complete blood count results showed transient decreases in white blood cell (WBC) counts for 2 of 4 F(ab′)
 <sub>2</sub>-treated NHPs (
 <xref ref-type="fig" rid="F3">Fig. 3A</xref>) but no substantial decreases in lymphocyte (LYM) counts or LYM percentages (
 <xref ref-type="fig" rid="F3">Fig. 3B</xref> and 
 <xref ref-type="fig" rid="F3">C</xref>). Increases in monocyte (MON) percentages and decreases in neutrophil (NEU) percentages were observed for all F(ab′)
 <sub>2</sub>-treated NHPs (
 <xref ref-type="fig" rid="F3">Fig. 3D</xref> and 
 <xref ref-type="fig" rid="F3">E</xref>). Changes in platelet (PLT) counts were not observed for any F(ab′)
 <sub>2</sub>-treated NHPs (
 <xref ref-type="fig" rid="F3">Fig. 3F</xref>). In contrast, control animals showed decreases in WBC counts, MON percentages, and PLT counts, as well as increased NEU percentages, during the course of the experiment.
</p>
